Cargando…

Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia

BACKGROUND: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against un...

Descripción completa

Detalles Bibliográficos
Autores principales: Alebachew, Mihreteab, Gelaye, Woyneshet, Abate, Megbaru Alemu, Sime, Heven, Hailgiorgis, Henok, Gidey, Bokretsion, Haile, Mebrahtom, Assefa, Gudissa, Bekele, Worku, Belay, Habtamu, Parr, Jonathan B., Tasew, Geremew, Mohammed, Hussein, Assefa, Ashenafi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276904/
https://www.ncbi.nlm.nih.gov/pubmed/37330475
http://dx.doi.org/10.1186/s12936-023-04618-y
Descripción
Sumario:BACKGROUND: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against uncomplicated Plasmodium falciparum in Northwest Ethiopia. METHODS: This single-arm prospective study with 42-day follow-up period was conducted from March to May 2021 at Hamusit Health Centre using the World Health Organization (WHO) therapeutic efficacy study protocol. A total of 90 adults ages 18 and older with uncomplicated falciparum malaria consented and were enrolled in the study. A standard single-dose regimen of pyronaridine-artesunate was administered daily for 3 days, and clinical and parasitological outcomes were assessed over 42 days of follow-up. Thick and thin blood films were prepared from capillary blood and examined using light microscopy. Haemoglobin was measured and dried blood spots were collected on day 0 and on the day of failure. RESULTS: Out of 90 patients, 86/90 (95.6%) completed the 42-day follow-up study period. The overall PCR-corrected cure rate (adequate clinical and parasitological response) was very high at 86/87 (98.9%) (95% CI: 92.2–99.8%) with no serious adverse events. The parasite clearance rate was high with fast resolution of clinical symptoms; 86/90 (95.6%) and 100% of the study participants cleared parasitaemia and fever on day 3, respectively. CONCLUSION: Pyronaridine-artesunate was highly efficacious and safe against uncomplicated P. falciparum in this study population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04618-y.